Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries (Q38876141)

7 September 2017

title

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries (English)

1 reference

7 September 2017

Mireia Diaz

0 references

Sue J Goldie

1 reference

7 September 2017

Meredith O'Shea

1 reference

7 September 2017

Nicole Gastineau Campos

series ordinal

1 reference

7 September 2017

Steven Sweet

series ordinal

1 reference

7 September 2017

Sun-Young Kim

series ordinal

1 reference

7 September 2017

language of work or name

English

0 references

publication date

15 May 2008

1 reference

7 September 2017

1 reference

inferred from page(s)

published in

Vaccine

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

4080-4093

1 reference

Chapter 1: HPV in the etiology of human cancer

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Chapter 8: Screening for cervical cancer in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Multiparameter Calibration of a Natural History Model of Cervical Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Cost-effectiveness of measles elimination in Latin America and the Caribbean: a prospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

Estimating the cost of cervical cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.053

10.1016/J.VACCINE.2008.04.053

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference